Specifically, PHLDA1 was highly expressed in the control group for bladder cancer, breast cancer, cholangiocarcinoma, renal papillary cell carcinoma, liver cancer, prostate cancer, and thyroid cancer, whereas it was highly expressed in the tumor groups for colorectal cancer, glioma, renal clear cell carcinoma, lung squamous cell carcinoma, rectal cancer, and gastric cancer (Figure 11B). Here, PHLDA1 is linked to urinary bladder carcinoma.